Approved labelIMCIVREE prescribing information for labeled genetic and syndromic obesity indications
PopulationAdults and pediatric patients covered by the approved IMCIVREE indications
DoseStarting and titration doses depend on age, indication, weight, tolerability, and kidney function. For adults and patients 12 years and older with BBS or POMC, PCSK1, or LEPR deficiency, the label starts at 2 mg once daily for 2 weeks and lists 3 mg once daily as maintenance if tolerated.
RouteSubcutaneous injection in the abdomen, thigh, or arm
FrequencyOnce daily at the beginning of the day
DurationLong-term use within the approved indication, with label-defined response assessment
PreparationReady-to-use 10 mg/mL solution in a 1 mL multiple-dose vial; no reconstitution.